The protocol describes how to measure knee hyperalgesia in mice. We show examples in mouse models of acute knee pain as well as in models of osteoarthritis (OA).
Method Article
The protocol describes how to measure knee hyperalgesia in mice. We show examples in mouse models of acute knee pain as well as in models of osteoarthritis (OA).
Assessment of knee hyperalgesia provides a robust assay for measuring peripheral sensitization in the knee, and represents a clinically relevant pain-dependent behavior that can be used in rodent models of arthritis. Several methods have been reported to determine the threshold for responses to knee compression in rodents. Here, we aimed to adapt existing methods to develop a standardized method for assessing knee hyperalgesia in adult mice, using a Pressure Application Measurement (PAM) device. The protocol includes detailed steps, training recommendations for new experimenters, and tips for achieving consistent results. We provide suggestions for optimal training of a new experimenter. Finally, representative outcomes are provided for both acute models of transient hyperalgesia and experimental osteoarthritis (OA) models, which are characterized by chronic pain. This method is highly sensitive to pharmacological interventions, making it suitable for evaluating the effects of mediators like cytokines and for medium-throughput drug screening assays. In summary, the described approach provides a robust and clinically relevant method for quantifying knee hyperalgesia.
Osteoarthritis (OA), the most common form of arthritis, is characterized by progressive cartilage degradation, synovitis, bone remodeling, and osteophyte growth1, and presents clinically as pain and loss of joint function. OA is one of the major sources of chronic pain in the world, profoundly impacting patients' lives due to reduced mobility and associated health issues such as anxiety and depression2,3. Commonly prescribed drugs for OA pain include nonsteroidal anti-inflammatory drugs (NSAIDs), visco-supplementation, corticosteroids, and opioids, but their efficacy is limited, and their prolonged use is associated with serious adverse effects or risk of addiction1,4.
In recent years, large cohort studies have attempted to carefully describe the pain experienced during progressive OA5. As part of this effort, several studies have performed quantitative sensory testing (QST) in subjects with OA, with the overall goal of identifying sensitization and determining associations between QST measures and OA symptoms and severity, as well as response to treatment (reviewed in6). The International Association for the Study of Pain defines sensitization as an increased responsiveness of nociceptive neurons to their normal input, and/or recruitment of a response to normally subthreshold inputs7. It is becoming increasingly clear that sensitization is a key process underlying chronic pain in OA. One particular QST finding that robustly distinguishes subjects with symptomatic OA from controls is a reduction in pain pressure threshold (PPT). A meta-analysis of PPT values (both at the knee and sites distant from the knee) of 1,003 participants with and without knee OA reported a significant standard mean difference (SMD, difference in means divided by standard deviation) in PPT between persons with OA and controls8.
The observation that OA patients display sensitization to mechanical stimuli, which is manifested as lowered pain pressure thresholds when a force is applied to the joint, suggests underlying mechanisms of peripheral and central sensitization that result from changes in the pain pathway6. The molecular and cellular underpinnings of these changes can be studied in rodent models of OA. In recent years, sophisticated mouse models have been developed to model the slowly progressive nature of knee OA, and this approach has revealed that distinct pain mechanisms operate in a time-dependent manner, which may have important translational significance9. For example, in the course of surgically induced experimental knee OA, mice develop mechanical allodynia in the operated hind paw early on in the course of the disease, while weight-bearing deficits only become apparent in late-stage disease9.
As in patients with OA, mice with experimental OA develop a lowered pain threshold for pain applied to the knee early on in the course of experimental knee OA10. This is indicative of sensitization of knee-innervating nociceptors, which can indeed be visualized and quantified by in vivo calcium imaging of the lumbar dorsal root ganglia11. Assessment of knee hyperalgesia provides a robust and relatively straightforward assay for measuring peripheral sensitization, thus representing a clinically relevant pain-dependent behavior that can be used in rodent models of arthritis. Several methods have been reported to determine the threshold for responses to knee compression in rodents. Older studies report squeezing the knee between the thumb and the forefinger, and recording a subjective withdrawal response or a vocalization response in the animal12,13,14 In 2007, Barton et al. reported pressure application measurement (PAM) as a novel behavioral technique to record mechanical hypersensitivity at the rat knee in inflammatory arthritis15. The method was subsequently validated in mice with antigen-induced arthritis of the knee 16. PAM is a technique that uses a force transducer to put an increasing force on the affected knee while providing visual feedback, thus enabling compression of the knee in a reproducible manner, which increases its sensitivity and reproducibility. These two previously published studies focused on models of inflammatory arthritis, where knee swelling is prominent. Therefore, we aimed to adapt these methods15,16 to develop a standardized method for assessing knee hyperalgesia in mice, which can be readily applied to models of OA and is highly responsive to pharmacological intervention, as described here.
Access restricted. Please log in or start a trial to view this content.
All experimental protocols were approved under the category E by the Rush University Institutional Animal Care and Use Committee. The protocol described is to assess knee hyperalgesia in the right knee in response to a mechanical stimulus in adult C57BL/6 mice (10 weeks- 2 years of age) of either sex. To measure knee hyperalgesia in the left knee, switch hands.
1. Setting up the Pressure Application Measurement (PAM) device
2. Training for measurement of knee hyperalgesia
3. Baseline measurement of knee hyperalgesia using PAM
NOTE: Many experimental models of inflammatory arthritis or osteoarthritis are unilateral (for example, surgically induced knee OA). To assess knee hyperalgesia in these models, we always measure knee withdrawal threshold first in the contralateral knee of all the mice to be tested. After that, we test the ipsilateral knee. As an example, this protocol can be applied to measure knee hyperalgesia in experimental OA induced by DMM. In this model, joint damage is accompanied by knee hyperalgesia, developing by week 2 after surgery, and maintained up to week 1617.
4. Measuring knee hyperalgesia in a model of acute knee pain
5. Longitudinal assessment of knee hyperalgesia in a protracted model of OA
Access restricted. Please log in or start a trial to view this content.
Time course of knee hyperalgesia in a model of acute knee pain
All results shown have been previously reported by our group, and we refer to10for a detailed description. The first example shows a model for inducing acute, transient knee hyperalgesia. In this experiment, we injected Pam3CSK4, a synthetic toll-like receptor 2 (TLR2) ligand (1 µg or 3 µg, dissolved in sterile water) at 5 µL, into the knee cavity of 10-week-old naïve male C57BL/6 mice, using a Hamilton syringe wit...
Access restricted. Please log in or start a trial to view this content.
Measurement of knee hyperalgesia in mice offers a relatively fast and straightforward means of assessing knee hyperalgesia associated with experimental arthritis. As can be observed from the representative results shown, the assay can detect acute onset and transient hyperalgesia (Figure 2A). We have reported this behavior in response to several mediators injected into the knee joint, including an aggrecan fragment10, a neurotrophin, nerve growth factor (NGF)
Access restricted. Please log in or start a trial to view this content.
AMM is a consultant for Novartis, Merck, Roivant, and Averitas. She has received research support from Orion and Eli Lilly. SI and REM have nothing to disclose.
Our research is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Grant/Award Numbers: P30AR079206 (AMM), R01AR060364 (AMM), R01AR064251 (AMM), UC2AR082186 (AMM), R21AR085242-01 (AMM), and R01AR077019 (REM).
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| C-C chemokine 2 receptor antagonist (CCR2RA) | Tocris | RS 504393 | |
| computer (any type) | windows 7 minimum | ||
| Lidocaine | Sigma | L5647 | |
| Pressure Application Measurement (P.A.M) | Ugo Basile | 38500 | included transducer, computer, cables |
| sandwich bag | whole food market | 6-1/2 x 5-7/8 | cover the transducer |
| toll-like receptor 2 ligand Pam3CSK4 | invitrogen | tlrl-pms |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request Permission